Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV
Reason given: Study not started as the IMP is re-worked by the manufacturer
Key facts
- Where
- Kampala, UgandaSee the 2 sites
- Phase
- Phase 1/2
Where in Uganda
- Baylor College of Medicine Children's FoundationKampala, UgandaNo longer taking part
- Joint Clinical Research Centre (JCRC)Kampala, UgandaNo longer taking part
Trial details
- Who runs it
- PENTA Foundation
- Trial code
- NCT06139796
- Record updated
- 5 March 2026
- Original description
The UNIVERSAL2 study is a research project designed to evaluate a newly developed formulation of an approved drug for children living with HIV aged over 3 years and weighing between 10 and 25 kg. The aim of UNIVERSAL2 is to determine the right dosage of this new formulation.Read full original descriptionShow less
Pharmacokinetics, Safety and Acceptability of a Solid Paediatric Fixed-dose Combination of Darunavir/Ritonavir (DRV/r) 120/20 mg for Children Living With HIV
The UNIVERSAL2 study is a research project designed to evaluate a newly developed formulation of an approved drug for children living with HIV aged over 3 years and weighing between 10 and 25 kg. The aim of UNIVERSAL2 is to determine the right dosage of this new formulation.
Inclusion: • Confirmed HIV-1 infection; Aged ≥ 3 years; With unsuppressed viral load (HIV-1 RNA viral load > 1000 c/mL) on ART-regimen and eligible to switch to new DRV/r 120/20 mg-based regimen per investigator's judgement; Able to swallow the 120/20 mg DRV/r tablets; Willing to receive the 120/20 mg DRV/r tablets; Parents or guardians, and children where appropriate, willing and able to give informed consent and to adhere to the protocol; Cohort-specific inclusion criteria:; Cohort A:; Have 1 or 2 DRV resistance-associated mutations (RAMs)*; Weigh 10 to <25 kg at screening; Cohort B:; Have no DRV RAMs*; Weigh 10 to <20 kg at screening. *DRV RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V.
Exclusion: Presence of >2 darunavir RAMs*; Failure of protease genotypic resistance testing at baseline, except if treatment history indicates that it is very unlikely; Resistance to all NRTI available in the country or impossibility to define an OBT; Intercurrent illness (enrolment can take place after the illness resolves); Creatinine ≥ 1.8 Upper Limit of Normal (ULN) or ALT ≥ 5 ULN or (ALT ≥ 3 ULN and bilirubin ≥2 ULN) at screening; Severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice), or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); History or presence of known allergy or other contraindication to DRV/r or their components as described in the Summary of Product Characteristics (SmPC); Concomitant medications that may interact with the current antiretroviral treatment, in particular TB drugs (i.e: rifampicin, rifabutin, rifapentine, …).